Cardiovascular safety of the glucagon-like peptide-1 receptor agonist taspoglutide in people with type 2 diabetes: an individual participant data meta-analysis of randomized controlled trials
- 5 February 2015
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 17 (5), 505-510
- https://doi.org/10.1111/dom.12448
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- The Cardiovascular Safety of Diabetes Drugs — Insights from the Rosiglitazone ExperienceNew England Journal of Medicine, 2013
- The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 DiabetesDiabetes Care, 2013
- Efficacy and Safety of Taspoglutide Monotherapy in Drug-Naive Type 2 Diabetic Patients After 24 Weeks of TreatmentDiabetes Care, 2012
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trialThe Lancet, 2010
- Incretin-Based Therapies: Review of Current Clinical Trial DataAmerican Journal Of Medicine, 2010
- The Extrapancreatic Effects of Glucagon-Like Peptide-1 and Related PeptidesJournal of Clinical Endocrinology & Metabolism, 2009
- Role and development of GLP-1 receptor agonists in the management of diabetesDiabetes, Metabolic Syndrome and Obesity, 2009
- Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trialsThe Lancet, 2009
- 10-Year Follow-up of Intensive Glucose Control in Type 2 DiabetesNew England Journal of Medicine, 2008
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998